GeoVax Labs (GOVX) AI Stock Analysis

• Market Cap: $6.18M
• Dividend Yield: N/A
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.12
• Revenue Growth: 8.52%
• EPS Growth: 79.51%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.75
• Shares Outstanding: 1,732,147
• 10 Day Avg. Volume: 1,123,459
• 30 Day Avg. Volume: 1,033,800
• PEG Ratio: <0.01
• Price to Book (P/B): 2.54
• Price to Sales (P/S): 3.24
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 38.00
• Enterprise Value/Revenue: 70.07
• Enterprise Value/Gross Profit: 71.25
• Enterprise Value/Ebitda: -9.31
• 1Y Price Target: $12.00
• Price Target Upside: 236.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.17 ▼(-95.38% Downside)

The score is primarily held down by weak financial performance (declining revenue, large losses, and significant cash burn) and bearish technicals (price below key moving averages with negative momentum). Potential upside from the earnings call (expedited regulatory path and partnership interest) provides some offset, but valuation remains constrained by ongoing losses and no dividend support.

Positive Factors

Vaccine Development Portfolio

GeoVax's robust vaccine development portfolio positions it to address unmet healthcare needs, potentially leading to expedited registration and market entry.

Strategic Partnerships

Strategic partnerships enhance GeoVax's global development and commercialization efforts, potentially increasing market reach and funding opportunities.

Cash Position

A strong cash position provides GeoVax with a buffer to manage operational expenses and invest in R&D, supporting long-term sustainability despite current challenges.

Negative Factors

BARDA Contract Termination

The BARDA contract termination poses a strategic setback, potentially affecting financial support and delaying vaccine development timelines.

Negative Cash Flow

Persistent negative cash flow highlights cash management challenges, necessitating reliance on external financing and raising concerns about financial sustainability.

Increased Expenses

Rising R&D and administrative expenses could strain financial resources, impacting profitability and necessitating careful cost management to ensure long-term viability.

GeoVax Labs Business Overview & Revenue Model

Company Description

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

How the Company Makes Money

GeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.

GeoVax Labs Financial Statement Overview

Summary

Financials reflect a development-stage biotech with sharply declining TTM revenue, deeply negative profitability, and persistent heavy cash burn (negative operating and free cash flow). The lack of debt reduces balance-sheet risk, but ongoing losses and reliance on external funding elevate dilution/funding risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined sharply (down ~45% vs. the prior year), while losses remain very large relative to revenue (net margin deeply negative). A positive is that reported gross margin is extremely high in 2024 and TTM, but operating and bottom-line profitability remain materially negative, indicating the business is still far from self-funding.

Balance Sheet

The balance sheet shows no debt in recent periods, which lowers financial risk and provides flexibility. However, equity is small and has trended down versus earlier years, and returns on equity are strongly negative, reflecting ongoing losses that continue to erode the capital base over time.

Cash Flow

Cash burn is persistent and heavy: operating cash flow and free cash flow are both around negative $24–25M in 2024 and TTM (Trailing-Twelve-Months). Free cash flow also deteriorated further in TTM, and cash generation does not cover operating needs, leaving the company reliant on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.35M	3.95M	0.00	81.53K	385.50K	1.82M
Gross Profit	3.30M	3.86M	-20.72M	-9.04M	385.50K	1.82M
EBITDA	-25.24M	-24.88M	-26.67M	-13.97M	-18.53M	-2.79M
Net Income	-25.31M	-24.99M	-25.97M	-14.02M	-18.57M	-2.96M
Balance Sheet
Total Assets	6.73M	8.16M	9.28M	31.35M	11.80M	10.39M
Cash, Cash Equivalents and Short-Term Investments	5.01M	5.51M	6.45M	27.61M	11.42M	9.88M
Total Debt	0.00	0.00	0.00	0.00	0.00	198.06K
Total Liabilities	1.82M	3.11M	3.52M	4.75M	7.43M	825.00K
Stockholders Equity	4.91M	5.05M	5.76M	26.60M	4.36M	9.57M
Cash Flow
Free Cash Flow	-24.27M	-24.70M	-25.22M	-19.16M	-11.24M	-2.91M
Operating Cash Flow	-24.27M	-24.68M	-25.17M	-19.03M	-11.20M	-2.75M
Investing Cash Flow	-27.61K	-20.65K	-48.95K	-134.26K	-47.72K	-156.79K
Financing Cash Flow	20.71M	23.75M	4.06M	35.35M	12.78M	12.51M

GeoVax Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 3.57 is below the 20-day moving average (MA) of 4.95, below the 50-day MA of 8.55, and below the 200-day MA of 17.30, indicating a bearish trend. The MACD of -1.35 indicates Negative momentum. The RSI at 28.17 is Positive, neither overbought nor oversold. The STOCH value of 13.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.

GeoVax Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LPCN	52 Neutral	$50.13M	-10.30	-32.92%	―	-44.31%	-34.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EDSA	50 Neutral	$12.33M	-1.10	-99.57%	―	―	30.29%
BLRX	48 Neutral	$12.45M	-2.10	-22.03%	―	-41.76%	87.36%
GOVX	44 Neutral	$6.18M	-0.07	-377.44%	―	8.52%	79.51%
SNGX	43 Neutral	$13.82M	-0.37	-169.32%	―	―	53.13%
LGVN	40 Underperform	$12.20M	-0.41	-119.92%	―	-22.41%	78.88%

GeoVax Labs Corporate Events

GeoVax Labs Executes Reverse Stock Split and Charter Amendments

On January 9, 2026, GeoVax Labs, Inc. implemented a 1-for-25 reverse stock split of its common stock, combining every 25 previously issued and outstanding shares into one new share with the same par value. No fractional shares were issued, with any resulting fractional positions rounded up to the next whole share, leaving shareholders’ overall percentage ownership and voting power essentially unchanged and the rights and privileges of common stockholders substantially unaffected.

The most recent analyst rating on (GOVX) stock is a Hold with a $0.16 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.

GeoVax Labs Announces Public Equity Offering for Liquidity

On December 19, 2025, GeoVax Labs, Inc. entered into agreements with Roth Capital Partners and a group of institutional and individual investors for a public offering of approximately 13.2 million common units, each consisting of one share of common stock and warrants to purchase additional shares, at a price of $0.245 per unit, with warrants exercisable immediately at the same price for five years. The transaction, which closed on December 22, 2025, is expected to generate about $3.2 million in gross proceeds and approximately $2.9 million in net proceeds, which GeoVax plans to use for working capital and general corporate purposes; the company also agreed to short-term restrictions on issuing additional equity and variable-rate securities, a move that shores up near-term liquidity while temporarily limiting further dilution and complex financings for existing shareholders.

The most recent analyst rating on (GOVX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.

GeoVax Labs Approves Share Issuance and Reverse Split

GeoVax Labs held a special meeting of stockholders on November 26, 2025, where they approved two significant proposals. The stockholders approved the issuance of up to 11,904,768 shares of common stock upon exercise of warrants issued in a private placement offering and an amendment for a reverse stock split at a ratio determined by the Board of Directors.

The most recent analyst rating on (GOVX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.